γδ T cells are a kind of innate immune T cell.They have not attracted sufficient attention because they account for only a small proportion of all immune cells,and many basic factors related to these cells remain unclear.However,in recent years,with the rapid development of tumor immunotherapy,γδ T cells have attracted increasing attention because of their ability to exert cytotoxic effects on most tumor cells without major histocompatibility complex(MHC)restriction.An increasing number of basic studies have focused on the development,antigen recognition,activation,and antitumor immune response of γδT cells.Additionally,γδ T cell-based immunotherapeutic strategies are being developed,and the number of clinical trials investigating such strategies is increasing.This review mainly summarizes the progress of basic research and the clinical application of γδT cells in tumor immunotherapy to provide a theoretical basis for further the development of γδ T cell-based strategies in the future.
Yueqi Zhao;Peng Dong;Wei He;Jianmin Zhang;Hui Chen
Department of Immunology,CAMS Key Laboratory for T Cell and Immunotherapy,State Key Laboratory of Medical Molecular Biology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences and School of Basic Medicine,Peking Union Medical College,Beijing 100005,ChinaChangzhou Xitaihu Institute for Frontier Technology of Cell Therapy,Changzhou,Jiangsu 213000,ChinaDepartment of Immunology,CAMS Key Laboratory for T Cell and Immunotherapy,State Key Laboratory of Medical Molecular Biology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences and School of Basic Medicine,Peking Union Medical College,Beijing 100005,China||Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy,Changzhou,Jiangsu 213000,China||Haihe Laboratory of Cell Ecosystem,Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin 300020,China
Gamma-delta T-cells;T cell receptor;CD1a;Tumor immunotherapy;Receptors,chimeric antigen;Vδ1 cells;αβ T cells
《中华医学杂志（英文版）》 2024 (001)
21-33 / 13
This work was supported by grants from the National Natural Science Foundation of China(Nos.32270915,31970843,82071791,U20A20374,and 81972886),the National Key Research and Development Program of China(No.2022YFC3602004),the CAMS Initiative for Innovative Medicine(Nos.2021-I2M-1-005,2021-I2M-1-035,and 2021-I2M-1-053),Haihe Laboratory of Cell Ecosystem Innovation Fund(No.22HHXBSS00028),the CAMS Central Public Welfare Scientific Research Institute Basal Research Expenses(No.3332020035),Changzhou Science and Technology Support Plan(No.CE20215008),and Beijing Municipal Commission of Science and Technology Fund for Innovative Drug(No.Z221100007922040).
10.1097/CM9.0000000000002781
评论